Skip to content
Nitinotes announces closing of an internal $7.1M series A1 funding
Bringing the total funds raised by Nitinotes to $13.5M, this funding will go towards finalizing the development of the Endozip automated suturing system, and execution of a multi-center pilot study in the EU.
Safety and Feasibility of a Novel Endoscopic Suturing Device (EndoZip TM) for Treatment of Obesity: First-in-Human Study
Endoscopic gastroplasty and gastric volume reduction techniques have been shown to achieve significant weight loss and improvement in comorbid conditions.
IFSO World Congress | Endozip’s FIH Study Selected Among Top 10 Abstracts In 2019
"Safety and Feasibility of a Novel Endoscopic suturing device For The treatment Of Obesity"
MedTech Strategist | A New Endoscopic Option for Patients with Obesity
Nitinotes is a member of a rising class of companies operating in endoscopic gastroenterology, which aim to help underserved patients that have diseases of the GI system.
The Times of Israel | Amid obesity, Israeli startup develops Endozip device to stitch up stomach bulge
Caesarea-based Nitinotes says it is working on a safe, automated, and minimally invasive suturing solution, tailor-made to help with weight reduction
Israel 21C | Treating obesity without going under the knife
Israel’s Nitinotes is developing a minimally invasive alternative to bariatric surgery.
Go to Top